Health Technology Assessment of Diagnostic Approaches in Alzheimer's

Status Completed

Clinical Trial Summary

Background: New research criteria for the diagnosis of Alzheimer's disease (AD) have recently been developed to enable an early diagnosis of AD pathophysiology by relying on emerging biomarkers. To enable efficient allocation of health care resources, evidence is needed to support decision makers on the adoption of emerging biomarkers in clinical practice. The research goals are to 1) assess the diagnostic test accuracy (of current clinical diagnostic work-up and emerging biomarkers in Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET) and Cerebrospinal Fluid (CSF), 2) perform a cost-consequence analysis and 3) assess long-term cost-effectiveness by an economic model.

Methods/design: In a cohort design 304 consecutive patients suspected of having a primary neurodegenerative disease are approached in four academic memory clinics and followed for two years. Clinical data and data on quality of life data, costs and emerging biomarkers are gathered.

Diagnostic test accuracy is determined by relating the clinical practice and new research criteria diagnoses to the reference diagnosis. The clinical practice diagnosis at baseline is reflected by a consensus procedure among experts using clinical information only (no biomarkers). The diagnosis based on the new research criteria is reflected by decision rules that combine clinical and biomarker information. The reference diagnosis is determined by a consensus procedure among experts based on clinical information on the course of symptoms over a two-year time period.

A decision analytic model is build combining available evidence from different resources among which (accuracy) results from the study, literature and expert opinion to assess long-term cost-effectiveness of the emerging biomarkers.

Discussion: Several other multi-centre trials study the relative value of new biomarkers for early evaluation of AD and related disorders. The uniqueness of this study is the assessment of resource utilization and quality of life to enable an economic evaluation. The study results are generalizable to a population of patients who are referred to a memory clinic due to their memory problems.

Clinical Trial Description

n/a

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01450891
Study type	Observational
Source	Maastricht University Medical Center
Contact
Status	Completed
Phase	N/A
Start date	September 2009
Completion date	July 2013

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05538455` - Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases	N/A
Completed	`NCT05788133` - The Role of Humanoid Robot in Neuropsychological Assessment and Cognitive Training.	N/A
Completed	`NCT05080777` - Pilot Pragmatic Clinical Trial to Embed Tele-Savvy Into Health Care Systems	N/A
Completed	`NCT03295786` - Clinical Study to Test the Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease	Phase 1/Phase 2
Recruiting	`NCT04265482` - Community-based Cohort of Functional Decline in Subjective Cognitive Complaint Elderly
Not yet recruiting	`NCT02222779` - Quantification of Transition Metals	N/A
Recruiting	`NCT01291550` - Electronic Nose for Diagnosis of Neurodegenerative Diseases Via Breath Samples	N/A
Completed	`NCT01953523` - Safety and Clinical Outcomes Study: SVF Deployment for Orthopedic, Neurologic, Urologic, and Cardio-pulmonary Conditions	N/A
Recruiting	`NCT06148233` - CSF1R PET Probe [18F]CSF-23 in Alzheimer's Disease Brain Imaging	N/A
Completed	`NCT03538522` - A Double-Blind, Placebo-Controlled Safety and Efficacy Study of NA-831	Phase 2
Completed	`NCT06251830` - Increasing Diagnosis Rates While Reducing Examination Time: Can MR Fingerprinting Deliver on Its Promise?
Recruiting	`NCT04472130` - Neurodegenerative Diseases Registry
Completed	`NCT03353207` - Striatal Dopamine Transmission in Individuals With Isolated Rapid Eye Movement Sleep With Atonia: a Search for Precursor Biomarker for Neurodegeneration
Completed	`NCT05095870` - Evaluation of the Peripheral Nerve Ultrasound as a Diagnostic Tool in CANVAS Neuropathies
Recruiting	`NCT05784090` - Correlation Between Melatonin Levels in Different Biological Fluids
Completed	`NCT02108769` - Yogic Breathing Changes Salivary Components	N/A
Recruiting	`NCT05508789` - A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)	Phase 3
Recruiting	`NCT04820881` - Cerebrovascular Reactivity and Oxygen Metabolism as Markers of Neurodegeneration After Traumatic Brain Injury
Recruiting	`NCT05235802` - Long-term Follow-up in Severe Traumatic Brain Injury
Completed	`NCT06180213` - Study of Cerebral Glucose Metabolism in Neurodegenerative Diseases and Head Trauma

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Health Technology Assessment of Diagnostic Approaches in Alzheimer's Disease

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms